anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
(R) -2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (Leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of he chemataxis of neutrophils and monocites induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of nutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.
The present invention discloses a compound of an Asiatic side local membrane forming gel, which comprises the components of the following weight percentages comprising 0.5% to 7% of alkyl cellulose, 1 percentage to 10% of etherifying agent, 0.5% to 5% of cross linking agent,70% to 90% of dissolvent, 0.5% to 10 % of Asiatic side. The cross linking agent is the saturated fat or the alcoholic acid, the chemical general formula of which is CnH(2n+2-m-l)(OH)m(COOH)l. Among the formula, m or n or 1 is the integer and the n is no less than m, which is no less than 2. l is no less than 0 and the result of m plus 1 is 4 to 8. The result of n plus 1 is 4 to 8. In the present invention, the compound of the Asiatic side local membrane forming gel is applied for promoting the wound healing and reducing the cicatrisation. A water drain protective membrane with smooth property, firm property, wear-resisting property and duration property is formed on the surface of the ulcer when the present invention is applied. Compared with all kinds of formulations of the Asiatic side in the present technique, the membrane formed by the gel compound is not likely to experience fracture, dissolution or corrosion. The membrane has properties of long maintenance time and slow releasing of the medicine.
The present invention improves operability during deployment of a sheet for skincare that is impregnated with a liquid. The sheet (1) for skincare according to one aspect of the present invention is accommodated in a package (90) in a folded state resulting when a sheet layer (2) having a basis weight of 45 g/m2 to 70 g/m2 (inclusive) is impregnated with 400-600 wt% (inclusive) of a liquid and the sheet layer (2) is folded with fold lines as reference points. The fold lines include a start fold line (FL1) that serves as a reference point for initial deployment when the sheet is deployed from the folded state. The sheet layer in the folded state has a cross direction (CD) that follows the start fold line, a longitudinal direction (LD) that is orthogonal to the cross direction, and a first region (10) and second region (20) that are disposed sandwiching the start fold line and that are layered on each other. The first region has a first longitudinal end edge (11) that is a longitudinal-direction end edge and that is positioned on the side opposite from the start fold line, and a first cross end edge (12) that is positioned on one cross-direction side. The second region (20) has a second longitudinal end edge (21) that is a longitudinal-direction end edge and that is positioned on the side opposite from the start fold line, and a second cross end edge (22) that is positioned on one cross-direction side. The first longitudinal end edge and the second longitudinal end edge are offset from each other in the longitudinal direction. The first cross end edge and the second cross end edge are offset from each other in the cross direction.
The participants will perform low-moderate intensity cycling exercise at 90% lactate threshold (LT) (determined during LT test) under normoxia (FiO2: 20.9%) for 60 minutes on a cycle ergometer. Immediately after exercise oral glucose tolerance test (OGTT) will be determined with 24-hour glucose concentration will be monitored continuously. Circulatory factors will be determined pre, immediately after exercise and 24 hours after exercise.
IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of \[18F\]-FBA-A20FMDV2 for the PET scanning in period 2.
A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
NEW MATERIAL:5-Fluoro-1-(2-trifluoromethylpropionyl)uracil of formula. USE:It has antitumor activity, and is useful as a carcinostatic agent or its intermediate. PROCESS:The compound of formula can be prepared, e.g. by adding the acid chloride of the corresponding trifluoromethylpropionic acid to the solution of 5-fluorouracil in a basic solvent, and reacting the components with each other. The basic solvent is, e.g. pyridine, triethylamine, etc. The reaction is carried out usually at room temperature, however, when the reaction is too vigorous, it is carried out at a low temperature, e.g. about -20 deg.C. In some cases, the reaction system is heated at 50 deg.C to complete the reaction.
All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
PURPOSE: To evaluate the causes of acute fluid misdirection (AFM) and the role of irido-zonulo-hyaloido-vitrectomy (IZHV) in the management of AFM.
METHODS: Among the 95,712 cataract surgeries performed between April 2017 and August 2022 at a tertiary center, six eyes of six patients developed intraoperative AFM and underwent IZHV through the anterior approach. AFM was diagnosed intraoperatively when there was sudden shallowing of the anterior chamber with markedly elevated intraocular pressures (IOPs) not attributable to external causes or choroidal effusion/hemorrhage. The condition resolved with deepening of AC following IZHV.
RESULTS: Five eyes had angle closure disease (one of them also had pseudoexfoliation), and one eye had open-angle glaucoma. The mean preop IOP was 25.8 ± 7.3 mmHg, with an IOP range of 18-36. The mean number of preop AGM was 3 ± 1.7. Four eyes developed AFM during combined cataract and trabeculectomy, and two eyes during cataract surgery. Four eyes had aqueous misdirection during or after cortical aspiration, and two eyes after creation of internal trabeculectomy ostium. IZHV was performed for all eyes through an anterior approach using a 23G vitrector, which resulted in instant resolution and deepening of the anterior chamber. The mean follow-up was 8.75 months (1-48 months), the mean postoperative IOP was 16.1 ± 2.6 mmHg, and the mean number of AGM at the last follow-up was 2.8 ± 2.2. The anterior chamber was deep, and IOP was under control in all eyes with four eyes needing AGM. One eye developed postoperative aqueous misdirection due to blockade of the IZHV opening.
CONCLUSION: IZHV can be an effective solution for acute intraoperative AFM, which can be performed via an anterior approach by the anterior segment surgeon.
* NORVIR must be used in combination with other antiretroviral agents.  

  * NORVIR is administered orally. NORVIR tablets should be swallowed whole, and not chewed, broken or crushed. Take NORVIR with meals.   

  * NORVIR oral powder should be mixed with soft food such as apple sauce or vanilla pudding, or mixed with liquid such as water, chocolate milk, or infant formula [see Dosage and Administration (2.4) and Instructions for Use]. The bitter aftertaste of NORVIR oral powder may be lessened if administered with food.
The invention provides a paramagnetic metal complex functionalized fluorogold nano-cluster magnetic resonance and fluorescence imaging contrast agent. The invention relates to the field of magnetic resonance imaging and fluorescence imaging contrast agents. With the contrast agent provided by the invention, problems of existing contrast agents of low relaxation efficiency, high toxicity, low tissue organ selectivity and fast in-vivo metabolism can be solved. According to the invention, ethylenediaminetetraacetic acid (EDTA) or diethylene triaminepentaacetic acid (DTPA) are connected to folic-acid-modified bovine serum albumin fluorogold nano-clusters through amide bonds; and EDTA or DTPA is respectively coordinated with paramagnetic metal ions, such that the complex is obtained. With the contrast agent provided by the invention, the relaxation efficiency can reach 23.7mM<-1>*s<-1>. The contrast agent has an advantage of low toxicity. According to the invention, high spatial resolution of magnetic resonance imaging and high sensitivity of fluorescence imaging are combined. Therefore, the contrast agent provided by the invention can be used in magnetic resonance imaging and fluorescence imaging.
Sepsis remains a leading cause of death worldwide with no proven immunomodulatory therapies. Stratifying Patient Immune Endotypes in Sepsis ('SPIES') is a prospective, multicenter observational study testing the utility of ELISpot as a functional bioassay specifically measuring cytokine-producing cells after stimulation to identify the immunosuppressed endotype, predict clinical outcomes in septic patients, and test potential immune stimulants for clinical development. Most ELISpot protocols call for the isolation of PBMC prior to their inclusion in the assay. In contrast, we developed a diluted whole blood (DWB) ELISpot protocol that has been validated across multiple laboratories. Heparinized whole blood was collected from healthy donors and septic patients and tested under different stimulation conditions to evaluate the impact of blood dilution, stimulant concentration, blood storage, and length of stimulation on ex vivo IFNγ and TNFα production as measured by ELISpot. We demonstrate a dynamic range of whole blood dilutions that give a robust ex vivo cytokine response to stimuli. Additionally, a wide range of stimulant concentrations can be utilized to induce cytokine production. Further modifications demonstrate anticoagulated whole blood can be stored up to 24 h at room temperature without losing significant functionality. Finally, we show ex vivo stimulation can be as brief as 4 h allowing for a substantial decrease in processing time. The data demonstrate the feasibility of using ELISpot to measure the functional capacity of cells within DWB under a variety of stimulation conditions to inform clinicians on the extent of immune dysregulation in septic patients.
• Instruct patients to read the Instructions for Use enclosed in the EGRIFTA SV Medication Box.  
• Use only the diluent provided, Sterile Water for Injection, to reconstitute EGRIFTA SV.  
• Reconstitute 1 vial of EGRIFTA SV lyophilized powder with 0.5 mL of diluent (2 mg per 0.5 mL). Mix by rolling the vial gently in your hands for 30 seconds. Do not shake.  
• Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use only if the solution is clear, colorless and without particulate matter.  
• Administer 0.35 mL of EGRIFTA SV immediately following reconstitution and throw away any unused solution and diluent. If not used immediately, discard the reconstituted solution. Do not freeze or refrigerate the reconstituted solution.
Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
BACKGROUND: Mirror movements (MM) are commonly caused by a defect of interhemispheric pathways also affected in multiple sclerosis (MS), particularly the corpus callosum. We investigated the prevalence of MM in MS in relation to functional and morphological callosal fiber integrity by transcranial magnetic stimulation (TMS), magnetic resonance imaging (MRI), as well as fatigue.
METHODS: In 21 patients with relapsing-remitting MS and 19 healthy controls, MM were assessed and graded (Woods and Teuber scale: MM 1-4) using a bedside test. Fatigue was evaluated using the Fatigue Scale for Motor and Cognitive Functions (FSMC) questionnaire. TMS measured ipsilateral silent period latency and duration. MRI assessed callosal atrophy by measuring the normalized corpus callosum area (nCCA), corpus callosum index (CCI), and lesion volume.
RESULTS: MS patients had significantly more often and pronounced MM compared to healthy controls (p = 0.0002) and nCCA was significantly lower (p = 0.045) in MRI studies. Patients with higher MM scores (MM > 1 vs. MM 0/1) showed significantly more fatigue (higher FSMC sum score, p = 0.04, motor score, p = 0.01). In TMS and MRI studies, no significant differences were found between patients with MM 0/1 and those with MM > 1 (ipsilateral silent period measurements, CCA, CCI and lesion volume).
CONCLUSIONS: MM are common in MS and can easily be detected through bedside testing. As MM are associated with fatigue, they might indicate fatigue in MS. It is possible that other cerebral structures, in addition to the corpus callosum, may contribute to the origin of MM in MS.
For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
Bilateral retinal metastasis is a rare disease that represents less than 1% of ocular metastases. Additionally, the prevalence of ocular metastases overall is only 5% to 10%. It is uncommonly found due to the absence of a lymphatic system in the eye. Ocular metastasis is spread hematogenously and the retina only receives 5% of blood flow, contributing to the rarity of this condition. Retinal metastasis has been reported to mimic symptoms of retinitis which include watery eye discharge, conjunctival injection and pain with ocular movement which leads to a harder diagnosis. Treatment options for retinal metastasis include systemic chemotherapy, intravitreal chemotherapy, and plaque radiotherapy. However, despite treatment, retinal metastasis often has a poor prognosis. This is a case of a 65-year-old woman with a history of breast carcinoma status post mastectomy who initially presented with metastatic infiltration of the lung and liver. However, she later developed an interesting case of retinal metastasis, which presented as symptoms of retinitis and indicated widespread dissemination of an unknown primary neoplasm.
Alzheimer's disease (AD) is a progressive neurodegenerative disease mostly affecting the elderly population. It is characterized by cognitive decline that occurs due to impaired neurotransmission and neuronal death. Even though deposition of amyloid beta (Aβ) peptides and aggregation of hyperphosphorylated TAU have been established as major pathological hallmarks of the disease, other factors such as the interaction of genetic and environmental factors are believed to contribute to the development and progression of AD. In general, patients initially present mild forgetfulness and difficulty in forming new memories. As it progresses, there are significant impairments in problem solving, social interaction, speech and overall cognitive function of the affected individual. Osteoarthritis (OA) is the most recurrent form of arthritis and widely acknowledged as a whole-joint disease, distinguished by progressive degeneration and erosion of joint cartilage accompanying synovitis and subchondral bone changes that can prompt peripheral inflammatory responses. Also predominantly affecting the elderly, OA frequently embroils weight-bearing joints such as the knees, spine and hips leading to pains, stiffness and diminished joint mobility, which in turn significantly impacts the patient's standard of life. Both infirmities can co-occur in older adults as a result of independent factors, as multiple health conditions are common in old age. Additionally, risk factors such as genetics, lifestyle changes, age and chronic inflammation may contribute to both conditions in some individuals. Besides localized peripheral low-grade inflammation, it is notable that low-grade systemic inflammation prompted by OA can play a role in AD pathogenesis. Studies have explored relationships between systemic inflammatory-associated diseases like obesity, hypertension, dyslipidemia, diabetes mellitus and AD. Given that AD is the most common form of dementia and shares similar risk factors with OA-both being age-related and low-grade inflammatory-associated diseases, OA may indeed serve as a risk factor for AD. This work aims to review literature on molecular mechanisms linking OA and AD pathologies, and explore potential connections between these conditions alongside future prospects and innovative treatments.
Herein described is a syringe assembly configured for the in situ lyophilization of an initial liquid preparation into a lyophilized product as well as the subsequent sealing of the lyophilized product for storage and transport, user reconstitution of the lyophilized product, and dispensing of the lyophilized product in rehydrated form to a patient in a medical setting, all in the same syringe. The combination lyophilization and dispensing syringe assemblies of the present invention greatly enhance the efficiency of the lyophilization process and find particular utility in conjunction with the dedicated lyophilization apparatus and methods described in U.S. Pat. Nos. 11,536,512 and 11,723,870. In particularly preferred embodiments, the present invention provides for shortened lyophilization cycles in a syringe barrel optionally fitted with a sealing Luer lock cap at its distal end and a vented stopper at its proximal end. During lyophilization, gas may flow out of the syringe barrel and through the stopper. After lyophilization, the stopper slid to its sealed position, thereby forming an airtight syringe whose contents are insulated from surrounding atmosphere and potential contamination. During the life cycle of the filled syringe, from seal to storage to transport, the lyophilized material is never exposed to the atmosphere. In addition, at time of use, an elongate stem may be threaded into the stopper to form a dispensing plunger in which the stopper acts as a sealing piston element In this manner, the assembly of syringe barrel, stopper and elongated stem constitute a fully functioning syringe that may be used to rehydrate and dispense the medicament of interest.
Peripheral artery disease (PAD) and its associated declines in physical function impair quality of life (QOL) in nearly 20% of older Veterans and result in substantial VA health care costs. Revascularization addresses the anatomical pathology, but does not restore mobility function and QOL. Optimal therapy may require post-revascularization rehabilitation to address lingering defects in skeletal muscle that limit function; however, the current standard of care after revascularization does not include rehabilitation. Exercise training and neuromuscular electrical stimulation (NMES) may enhance function by increasing muscle perfusion to improve outcomes in older Veterans with PAD after revascularization.

The investigators will enroll Veterans (50-80 years of age) with PAD who are planned for percutaneous revascularization. Participants will complete research testing consisting of: a) Assessment of mobility function and QOL; and b) Treadmill tests to assess ambulatory capacity, and calf muscle perfusion. Participants will undergo screening prior to revascularization and will have baseline testing 2-3 weeks after revascularization. After post-revascularization testing, patients will be randomized to Exercise-only or NMES-only. After completion of the 3-month intervention, participants will repeat all tests to determine the effects of the interventions.
Investigators propose to do a randomized feasibility trial comparing RP vs RT to the prostate in the setting of hormone sensitive oligometastatic prostate cancer. SBRT will be used to treat all of the metastases, and this will be combined with an intermittent ADT approach. Adding systemic chemotherapy will be allowed. Given the past difficulties of randomizing patients between RP and RT in localized prostate cancer studies (like SPIRIT), investigators feel a small feasibility project is the first step. In the setting of metastatic disease, where radical treatment is not routine standard of care, we hope that patients will be more inclined to accept randomization. If patients do not accept their assigned randomization (ie they prefer RP even though they are randomized to RT, or vice versa), they will still be treated with their prostate intervention of choice and followed for their outcomes.
This is a multi-center, randomized, placebo-controlled, double-masked study of 166 evaluable participants taking buspirone twice daily for 6 months. Children aged 2-6 years with autism will be randomized to receive one of three treatments: 2.5mg, 5.0mg, or matched placebo. The placebo controlled trial will be followed by an optional follow-up trial to assess the long term safety of buspirone. In addition, a PET scan of serotonin synthesis and plasma serotonin will be measured at baseline to determine whether these measures are predictors of drug response. This trial is aimed at the core features of autism. The outcome measures for efficacy will be examiner and parent ratings on psychological tests and questionnaires. The outcome measure for the primary objective will be the Autism Diagnostic Observation Scale (ADOS) Composite Total score. The behavioral outcomes for the secondary aims are delineated in the study design.
PURPOSE: Plant extract composition containing ecdysteroids and iridoids and its use are provided. Specifically extracts of Ajuga turestanica, Auga decumbens, Phaponica cartammoides and Selena primicta and their compositions in which ecdysteroids and iridoids are contained in 1:3-1:10 wt. ratio are used in medicine, cosmetics, food and drinks. These extracts promote the production of mother's milk, protein and resistance against stress and have tonic effect. They also have excellent moisturizing and skin improving effect by enhancing top skin cell division. CONSTITUTION: In a conventional method of extraction, 62% of ecdysteroids and all the iridoids are lost during the various steps of extraction. This invention uses 80-90% alcohol to extract the component from the powder of the plant; concentrates by heating under 60 deg.C under vacuum and eliminates alcohol and dilutes with water; removes the oil soluble compositions from this water solution by extracting with chloroform or benzene; adds alcohol to dilute this solution to make 20-60% alcoholic solution and filters through ultra-membrane with 10,000 dalton pore size for final use. This way the extraction process is simplified and economical. 0.001-10wt.% of the extract is used in the product composition.